Sytze De Roock

Dr. Sytze De Roock


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2016 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
AVAnouk Verwoerd
Anouk Verwoerd
NHNienke M. Ter Haar
Nienke M. Ter Haar
SRSytze De Roock
Sytze De Roock
SVSebastiaan Vastert
Sebastiaan Vastert
DBDebby Bogaert
Debby Bogaert
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. The pathogenesis of JIA is thought to be the result of a combination of host genetic and environmental triggers. However, the precise factors that determine one’s susceptibility to JIA remain to be unravelled. The microbiome has received increasing attention as a potential contributing factor to the development of a wide array of immune-mediated diseases, including inflammatory bowel disease, type 1 diabetes and rheumatoid arthritis. Also in JIA, there is accumulating evidence that the composition of the microbiome is different from healthy individuals. A growing body of evidence indeed suggests that, among others, the microbiome may influence the development of the immune system, the integrity of the intestinal mucosal barrier, and the differentiation of T cell subsets. In turn, this might lead to dysregulation of the immune system, thereby possibly playing a role in the development of JIA. The potential to manipulate the microbiome, for example by faecal microbial transplantation, might then offer perspectives for future therapeutic interventions. Before we can think of such interventions, we need to first obtain a deeper understanding of the cause and effect relationship between JIA and the microbiome. In this review, we discuss the existing evidence for the involvement of the microbiome in JIA pathogenesis and explore the potential mechanisms through which the microbiome may influence the development of autoimmunity in general and JIA specifically.

30 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
JWJudith Wienke
Judith Wienke
WJWillemijn Janssen
Willemijn Janssen
RSRianne Scholman
Rianne Scholman
HSHilde Spits
Hilde Spits
MGMarielle van Gijn
Marielle van Gijn
SRSytze De Roock
Sytze De Roock
A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation

8 January 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GKGerdien A.H. Korte-Bouws
Gerdien A.H. Korte-Bouws
EAEline Albers
Eline Albers
MVMarije Johanna Voskamp
Marije Johanna Voskamp
HHHendrikus Hendriksen
Hendrikus Hendriksen
LLLidewij R. De Leeuw
Lidewij R. De Leeuw
KSKorte S.M.
Korte S.M.
Juvenile idiopathic arthritis (JIA) represents joint inflammation with an unknown cause that starts before the age of 16, resulting in stiff and painful joints. In addition, JIA patients often report symptoms of sickness behavior. Recent animal studies suggest that proinflammatory cytokines produce sickness behavior by increasing the activity of indoleamine-2,3-dioxygenase (IDO) and guanosinetriphosphate–cyclohydrolase-1 (GTP–CH1). Here, it is hypothesized that inflammation in JIA patients enhances the enzymatic activity of IDO and GTP-CH1 and decreases the co-factor tetrahydrobiopterin (BH4). These compounds play a crucial role in the synthesis and metabolism of neurotransmitters. The aim of our study was to reveal whether inflammation affects both the GTP-CH1 and IDO pathway in JIA patients. Serum samples were collected from twenty-four JIA patients. In these samples, the concentrations of tryptophan (TRP), kynurenine (KYN), tyrosine (TYR), neopterin, and phenylalanine (PHE) were measured. An HPLC method with electrochemical detection was developed to quantify tryptophan, kynurenine, and tyrosine. Neopterin and phenylalanine were quantified by ELISA. The KYN/TRP ratio was measured as an index of IDO activity, while the PHE/TYR ratio was measured as an index of BH4 activity. Neopterin concentrations were used as an indirect measure of GTP-CH1 activity. JIA patients with high disease activity showed higher levels of both neopterin and kynurenine, and a higher ratio of both KYN/TRP and PHE/TYR and lower tryptophan levels than clinically inactive patients. Altogether, these data support our hypothesis that inflammation increases the enzymatic activity of both IDO and GTP-CH1 but decreases the efficacy of the co-factor BH4. In the future, animal studies are needed to investigate whether inflammation-induced changes in these enzymatic pathways and co-factor BH4 lower the levels of the brain neurotransmitters glutamate, noradrenaline, dopamine, serotonin, and melatonin, and consequently, whether they may affect fatigue, cognition, anxiety, and depression. Understanding of these complex neuroimmune interactions provides new possibilities for Pharma-Food interventions to improve the quality of life of patients suffering from chronic inflammation.

1 December 2011 in Clinical Nutrition
Verified
Journal Article
Closed access
SRSytze De Roock
Sytze De Roock
MEMerel van Elk
Merel van Elk
MHMaarten O. Hoekstra
Maarten O. Hoekstra
BPBerent J. Prakken
Berent J. Prakken
GRGer T. Rijkers
Ger T. Rijkers
IKIsmé M. de Kleer
Ismé M. de Kleer

1 September 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
SRSytze De Roock
Sytze De Roock
ASArie Stoppelenburg
Arie Stoppelenburg
RSRianne Scholman
Rianne Scholman
SHSanne B.E.A. Hoeks
Sanne B.E.A. Hoeks
JMJenny Meerding
Jenny Meerding
MBMarianne Boes
Marianne Boes

1 January 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
JSJoost F Swart
Joost F Swart
SRSytze De Roock
Sytze De Roock
NWNico M Wulffraat
Nico M Wulffraat
This review summarizes the immunological consequences of biological therapies used in juvenile idiopathic arthritis (JIA). For every frequently used biological agent the characteristics are clearly specified (molecular target, isotype, registered indication for JIA, route of administration, half-life, contraindication, very common side effects, expected time of response and average cost in the first year). The emphasis of this review is on the immunological side effects that have been encountered for every separate agent in JIA populations. For each agent these adverse events have been calculated as incidence per 100 patient-years for the following categories: serious infections, tuberculosis, malignancies, response to vaccination, new-onset autoimmune diseases and development of anti-drug antibodies. There are large differences in side effects between various agents and there is a clear need for an international and standardized collection of post-marketing surveillance data of biologicals in the vulnerable group of JIA patients. Such an international pharmacovigilance database, called Pharmachild, has now been started.